antiviral and associated therapy - versus potential COVID-19 treatments - for COVID 19 hospitalized pdf   xlsx method abbreviations

Outcome Relative effect 95%CI LoD Trt. better when I2 k (RCT/OBS) Bayesian probability Overall ROB Publication bias Degree of certainty Endpoint importance Published MA

efficacy endpoints 00

death D28 1.01 [0.94, 1.08]< 10%19 studies (19/-)41.0 %some concernlow moderatecrucial-
death or transfer to ICU 1.09 [0.99, 1.20]< 10%2 studies (2/-)4.0 %some concernnot evaluable moderatecrucial-
deaths 0.98 [0.93, 1.03]< 10%79 studies (79/-)79.1 %some concerncritical moderatecrucial-
deaths (time to event analysis only) 0.93 [0.84, 1.04]< 143%13 studies (13/-)89.9 %some concerncritical moderatecrucial-
clinical deterioration 0.99 [0.81, 1.21]< 14%16 studies (16/-)53.3 %some concernlow moderateimportant-
clinical improvement 1.16 [1.00, 1.34]> 160%23 studies (23/-)97.7 %some concernlow moderateimportant-
clinical improvement (14-day) 1.11 [0.94, 1.30]> 147%19 studies (19/-)89.0 %some concernlow moderateimportant-
clinical improvement (21-day) 2.09 [0.04, 119.96]> 10%1 study (1/-)63.7 %NAnot evaluable important-
clinical improvement (28-day) 1.24 [1.03, 1.50]> 154%9 studies (9/-)98.8 %some concernnot evaluable moderateimportant-
clinical improvement (7-day) 1.18 [1.00, 1.39]> 148%15 studies (15/-)97.5 %some concerncritical moderateimportant-
clinical improvement (time to event analysis only) 1.17 [1.04, 1.31]> 158%18 studies (18/-)99.5 %some concernlow moderateimportant-
death or ventilation 1.02 [0.95, 1.10]< 114%9 studies (9/-)27.9 %some concernnot evaluable moderateimportant-
hospital discharge 1.00 [0.93, 1.08]> 145%17 studies (17/-)52.5 %some concernlow moderateimportant-
hospitalization 0.25 [0.08, 0.83]< 10%2 studies (2/-)98.8 %NAnot evaluable important-
mechanical ventilation 0.89 [0.71, 1.12]< 142%24 studies (24/-)84.2 %some concerncritical moderateimportant-
mechanical ventilation (time to event analysis only) 0.06 [0.01, 0.83]< 10%1 study (1/-)98.2 %NAnot evaluable important-
radiologic improvement (14-day) 1.22 [0.77, 1.92]> 127%5 studies (5/-)80.3 %some concernnot evaluable moderateimportant-
radiologic improvement (7-day) 0.45 [0.07, 3.02]> 169%5 studies (5/-)20.8 %some concernserious moderateimportant-
viral clearance 1.24 [0.97, 1.58]> 162%18 studies (18/-)95.8 %some concernlow moderateimportant-
viral clearance (time to event analysis only) 1.28 [0.92, 1.78]> 167%8 studies (8/-)93.1 %some concernnot evaluable moderateimportant-
viral clearance by day 14 1.04 [0.94, 1.16]> 110%12 studies (12/-)77.0 %some concernlow moderateimportant-
viral clearance by day 7 1.13 [0.86, 1.47]> 158%14 studies (14/-)80.9 %some concernlow moderateimportant-
ICU admission 0.96 [0.76, 1.22]< 114%15 studies (15/-)62.7 %some concernlow moderatenon important-
off oxygenation 0.98 [0.64, 1.51]> 10%1 study (1/-)46.4 %NAnot evaluable non important-
recovery 1.04 [0.91, 1.20]> 153%6 studies (6/-)72.3 %some concernnot evaluable moderatenon important-
severe COVID-19 occurrence 0.30 [0.07, 1.27]< 10%1 study (1/-)94.9 %NAnot evaluable non important-

safety endpoints 00

AE leading to drug discontinuation 2.43 [0.79, 7.45]< 10%1 study (1/-)6.0 %NAnot evaluable important-
cardiac arrest 1.92 [0.35, 10.49]< 10%1 study (1/-)22.7 %NAnot evaluable important-
related SAE (TRSAE) 1.24 [0.50, 3.11]< 10%1 study (1/-)32.0 %NAnot evaluable important-
serious adverse events 0.85 [0.71, 1.01]< 10%23 studies (23/-)96.9 %some concerncritical moderateimportant-
acute kidney injury 1.18 [0.44, 3.18]< 10%1 study (1/-)37.2 %NAnot evaluable non important-
adverse events 1.82 [1.40, 2.38]< 160%24 studies (24/-)0.0 %some concerncritical moderatenon important-
arrhythmia 0.91 [0.72, 1.15]< 10%3 studies (3/-)78.1 %some concernnot evaluable moderatenon important-
deep vein thrombosis 0.62 [0.23, 1.64]< 10%2 studies (2/-)83.1 %some concernnot evaluable moderatenon important-
elevated liver enzymes 0.95 [0.29, 3.10]< 184%3 studies (3/-)53.6 %some concernnot evaluable moderatenon important-
hyperbilirubinemia 0.97 [0.48, 1.93]< 10%2 studies (2/-)53.8 %lownot evaluable highnon important-
long QT 2.39 [0.24, 23.87]< 180%2 studies (2/-)23.0 %some concernnot evaluable moderatenon important-
pulmonary embolism 0.82 [0.20, 3.29]< 10%2 studies (2/-)61.1 %some concernnot evaluable moderatenon important-
renal impairment 1.26 [0.95, 1.67]< 10%4 studies (4/-)5.6 %some concernnot evaluable moderatenon important-
serious adverse events (SAE), any 0.50 [0.32, 0.79]< 10%1 study (1/-)99.9 %NAnot evaluable non important-
severe adverse events 1.10 [0.07, 18.09]< 10%2 studies (2/-)47.4 %highnot evaluable lownon important-

AE of interest endpoints 00

Thromboembolic events 0.89 [0.31, 2.55]< 10%1 study (1/-)58.6 %NAnot evaluable non important-

LoD: level of statistical demonstration: Statistically conclusive: statistically significant with a strict control of overall risk of type 1 error (statistically demonstrated), does not take into account the risk of bias; suggested: nominally statistically significant but without a strict control of overall risk of type 1 error; inconclusive: not nominally statistically significant; safety concerns;
Bayesian probability: Bayesian posterior probability of treatment effect (computed with a noninformative prior); ROB: risk of bias; k: number of studies; published MA: number of published meta-analysis on the same topic; degree of certainty adapted from GRADE. Trt. better when: indicates when the relative treatment effect shows that the studied treatment is better than control.